New drug combo aims to tame rare blood cancer and prep for transplant
NCT ID NCT00492050
First seen Oct 31, 2025 · Last updated Jun 22, 2026 · Updated 44 times
Summary
This Phase 2 trial tests bortezomib (Velcade) and rituximab (Rituxan) as an initial treatment for Waldenstrom's macroglobulinemia, a rare blood cancer. The goal is to control the disease and collect stem cells for a possible future transplant. The study involves 46 participants and will measure how well the cancer responds after 2-3 cycles of treatment.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for WALDENSTROM'S MACROGLOBULINEMIA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
University of Texas MD Anderson Cancer Center
Houston, Texas, 77030, United States
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
bortezomib (Velcade) and rituximab (Rituxan)
What this could lead to
If successful, this combination could help control Waldenstrom's macroglobulinemia and allow stem cell collection for future transplant if the disease worsens.
What could go wrong
This is a small Phase 2 trial with only 46 participants, so results may not apply to everyone. The treatment may not work for all, and side effects from the drugs are possible.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.